News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.
Photo from Andres Gomez/Twitter
Aug 29, 2023, 19:15

Andres Gomez: Venetoclax can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Andres Gomez, an Associate Professor at Universidad Autónoma de Nuevo León, Mexico, recently tweeted:

“Venetoclax is an expensive life-saving drug in AML. We have proven it can be effectively reduced to 100 mg when combined with azoles in a first-line, phase 2 trial done under limited resources.

Out now in Leuk Res, access here:”

Source: Andres Gomez/Twitter

Andres Gomez cancer OncoDaily Oncology Twitter venetoclax
Special Coverage
Insight
Dec 22, 2024, 05:22
Camilla Perucchini: I have officially graduated with a Master of Science in Biotechnology curriculum
Career
Dec 22, 2024, 05:19
Sidra Naz has been honored with the 2025 Early Career Investigator Award in Healthcare Disparities Research in IBD
Blog
Dec 22, 2024, 05:17
Rasha Aboelhassan: Oncologists are overwhelmed by their own fights against cancer
Blog
Dec 22, 2024, 05:15
Jemma Arakelyan: Collaboration plans between City University of Hong Kong and Shenzhen Hospital of Southern Medical University
Blog
Dec 22, 2024, 05:13
The Connell and O’Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute
Blog
Dec 22, 2024, 05:05
Ruben Mesa: Excited to visit Atrium Health Levine Cancer Pineville
Blog
Dec 22, 2024, 05:02
Muhammad Umair Mushtaq: Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70?
Blog
Dec 22, 2024, 05:00
Elvina Almuradova: Being a part of Giuseppe Curigliano's team is an invaluable scientific milestone for me
Blog
Dec 22, 2024, 04:58
Summary slide for PFS in selected trials by IGHV status caveat for CLL by Nitin Jain
Insight
Dec 22, 2024, 04:53
Cancer survivors are growing in number - National Cancer Institute
Blog
Dec 22, 2024, 04:52
Registration is open for the ESMO Gastrointestinal Cancers Congress 2025
Blog
Dec 22, 2024, 04:49
Amalya Sargsyan: New ESO Rare Cancer Series podcast with Salvatore Provenzano